

**Boxenbaum 1974** Boxenbaum HG, Riegelman S. 1974. Determination of isoniazid and metabolites in biological fluids. J Pharm Sci 63:1191–1197. http://dx.doi.org/10.1002/jps.2600630804.

**Cordes 2016** Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L. 2016. A physiologically based pharmacokinetic model of isoniazid and its application in individualizing tuberculosis chemotherapy. Antimicrob Agents Chemother 60(10):6134-45. http://doi.org/10.1128/AAC.00508-16

**Chen 2011** Chen B, Cao X, Li J. 2011. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metabol Drug Interact 26:113–118. http://dx.doi.org/10.1515/DMDI.2011.016.

**Ellard 1973** Ellard GA, Gammon PT, Tiitinen H. 1973. Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid
to acid-labile isoniazid: a study in Finnish Lapland. Tubercle 54:201–210. http://dx.doi.org/10.1016/0041-3879(73)90025-1.

**Ellard 1976** Ellard GA, Gammon PT. 1976. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 4:83–113. http://dx.doi.org/10.1007/BF01086149.

**Kubota 2007** Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. 2007. Dose escalation study of isoniazid in healthy volunteers with the rapid acetylatorgenotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 63:927–933. http://dx.doi.org/10.1007/s00228-007-0333-1.

**Kubota 1991** Kubota K, Ishizaki T. 1991. Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol 41:363–368. http://dx.doi.org/10.1007/BF00314969.

**Kuepfer 2016** Kuepfer 2016 Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Herrera 1990**  Herrera AM, Scott DO, Lunte CE. 1990. Microdialysis sampling for determination of plasma protein binding of drugs. Pharm Res 7:1077–1081. http://dx.doi.org/10.1023/A:1015955503708.

**Lauterburg 1981** Lauterburg BH, Smith CV, Mitchell JR. 1981. Determination of isoniazid and its hydrazino metabolites, acetylisoniazid, acetylhydrazine, and diacetylhydrazine in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 224:431– 438. http://dx.doi .org/10.1016/S0378-4347(00)80216-9.

**Lauterburg 1985** Lauterburg BH, Smith CV, Todd EL, Mitchell JR. 1985. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235:566 –570.

**MarvinSketch V15.11.3** MarvinSketch; Version 15.11.30.0; ChemAxon Kft., Budapest, Hungary

**Meyer 2012** Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. 2012. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos 40:892–901.

**Mitchell 1975a** Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR. 1975. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.Clin Pharmacol Ther 18:70 –79. http://dx.doi.org/10.1002/cpt197518170.

**Mitchell 1975b** Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter 178 WZ, Jollow HR, Keiser HR. 1975. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 180 18:70–9.

**Pea 1999** Pea F, Milaneschi R, Baraldo M, Talmassons G, Furlanut M. 1999.Isoniazid and its hydrazine metabolite in patients with tuberculosis. Clin Drug Invest 17:145–154. http://dx.doi.org/10.2165/00044011-199917020
-00009.

**Peretti 1987** Peretti E, Karlaganis G, Lauterburg BH. 1987. Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant
administration of isoniazid. J Pharmacol Exp Ther 243:686–689.

**PK-Sim Ontogeny Database Version 7.3** PK-Sim Ontogeny Database Version 7.3 (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**van der Wethuizeb 2000** van der Westhuizen FH, Pretorius PJ, Erasmus E. 2000. The utilization of alanine, glutamic acid, and serine as amino acid substrates for glycine N-acyltransferase. J Biochem Mol Toxicol 14:102–109.

**von Sassen 1985** von Sassen W, Castro-Parra M, Musch E, Eichelbaum M. 1985. Determination of isoniazid, acetylisoniazid, acetylhydrazine and diacetylhydrazine in biological fluids by high-performance liquid chromatography. J
Chromatogr 338:113–122. http://dx.doi.org/10.1016/0378-4347
(85)80075-X.

**Uchino 2002** Uchino H. 2002. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729 –737. http://dx.doi.org /10.1124/mol.61.4.729.

**Willman 2007** Willmann 2007 Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007, 34(3): 401-431.

